The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However, due to differences in clinical processes and insurance systems in each country, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe, […]

With the arrival of new therapeutic tracers, nuclear medicine has a new arsenal to treat metastatic bone pain. This presentation aims to give the keys to define the place of nuclear medicine among other treatment modalities (external beam therapy, medical treatment, chemotherapy). Learning Objectives: Refresh knowledge on the pathophysiology of pain and present the opportunities […]